PMID- 26174898
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20150716
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 55 Suppl 2
DP  - 2015 Jul
TI  - Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues 
      obtained from review of clinical case reports.
PG  - S59-64
LID - 10.1111/trf.13090 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is an efficacious treatment 
      modality for a number of conditions and is usually well tolerated with few 
      reports of serious adverse events; however, the administration of IVIG may 
      occasionally result in clinically significant hemolysis. STUDY DESIGN AND 
      METHODS: The literature was reviewed for case reports and case series of 
      IVIG-associated hemolysis. The cases were scrutinized for clues as to the 
      possible mechanism(s) of the hemolysis. RESULTS: Review of the 129 individual 
      cases reported in the literature identifies clinical features shared by the 
      majority of patients. These features included non-O blood group patients and 
      treatment with high-dose IVIG as an immune-modulating agent for an underlying 
      inflammatory or immune-mediated disorder. Other patient factors such as secretor 
      phenotype, soluble ABH substance, and Fcgamma receptor polymorphisms may also 
      play a role. CONCLUSIONS: It is known that high-dose IVIG given to non-O blood 
      group patients with underlying inflammatory and/or immune-mediated disorders is 
      associated with increased risk of hemolysis. This review reveals additional 
      patient characteristics in cases of IVIG-associated hemolysis, including 
      underrepresentation of D- and group B cases, higher incidence in pediatric 
      Kawasaki disease and unique at-risk patient groups including allogeneic stem cell 
      transplant recipients with group A donor in a group O recipient, and patients in 
      whom soluble AB substance is removed by plasma exchange at the same time as 
      receiving IVIG.
CI  - (c) 2015 AABB.
FAU - Padmore, Ruth
AU  - Padmore R
AD  - Ottawa Hospital and Eastern Ontario Regional Laboratory Association and 
      University of Ottawa, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (ABO Blood-Group System)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - *ABO Blood-Group System/immunology
MH  - Adult
MH  - Allografts
MH  - Female
MH  - Hemolysis/drug effects/genetics/immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects/immunology/therapeutic use
MH  - Immunologic Factors/*adverse effects/immunology/therapeutic use
MH  - Incidence
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/drug therapy/genetics/immunology
MH  - *Polymorphism, Genetic
MH  - *Receptors, IgG/genetics/immunology
MH  - Stem Cell Transplantation
EDAT- 2015/07/16 06:00
MHDA- 2015/09/29 06:00
CRDT- 2015/07/16 06:00
PHST- 2014/10/15 00:00 [received]
PHST- 2015/02/23 00:00 [revised]
PHST- 2015/02/27 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - 10.1111/trf.13090 [doi]
PST - ppublish
SO  - Transfusion. 2015 Jul;55 Suppl 2:S59-64. doi: 10.1111/trf.13090.